Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction

Daisuke Kamimura1, Tomohito Ohtani, Yasushi Sakata

  • 1Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

European Heart Journal
|April 15, 2011
PubMed

Insights

Digitalis-like factors contribute to heart failure with preserved ejection fraction (HFPEF) by promoting cardiac fibrosis. Inhibiting the Na+/Ca2+ exchanger (NCX) entry mode with SEA0400 effectively prevents fibrosis and improves survival in a rat model of hypertensive HFPEF.

Area of Science:

  • Cardiovascular Physiology
  • Cardiac Fibrosis Research
  • Pharmacology

Background:

  • Left ventricular (LV) fibrosis and stiffening are key factors in heart failure with preserved ejection fraction (HFPEF).
  • Elevated plasma digitalis-like factors (DLFs) in hypertension, a common cause of HFPEF, are linked to Na+/K+-ATPase inhibition and Na+/Ca2+ exchanger (NCX) activation.
  • DLFs are known to stimulate collagen production in cardiac fibroblasts.

Purpose of the Study:

  • To investigate if pharmacological inhibition of the NCX entry mode can prevent LV fibrosis and the development of HFPEF.
  • To explore the role of DLFs and NCX in hypertensive HFPEF.

Main Methods:

  • Utilized Dahl salt-sensitive rats on an 8% NaCl diet as a model for hypertensive HFPEF.
  • Administered ouabain to Sprague-Dawley rats to induce LV fibrosis and studied its effects on intracellular Ca2+ and cardiac fibroblasts.
  • Tested SEA0400, an NCX entry mode inhibitor, in both ouabain-treated rats and the HFPEF model.

Main Results:

  • Dahl rats showed increased DLF excretion during HFPEF development.
  • Ouabain induced LV fibrosis, increased intracellular Ca2+ via NCX, and enhanced collagen synthesis in fibroblasts; SEA0400 counteracted these effects.
  • In the HFPEF model, SEA0400 administration improved survival rates and reduced LV fibrosis and stiffening without lowering blood pressure.

Conclusions:

  • Digitalis-like factors and activated NCX entry mode are implicated in the pathogenesis of hypertensive HFPEF.
  • Blocking the NCX entry mode presents a potential novel therapeutic strategy for HFPEF.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
642
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635